QUADRA: A phase 2, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) who have received ≥3 prior chemotherapy regimens.

Authors:

Abstract
5514Background: PARP inhibitors (PARPi) are approved as active treatment only for pts with BRCA mutations. The PARPi niraparib demonstrated increased PFS vs placebo in the maintenance setting of platinum (plat) responsive ROC. Niraparib was effective regardless of BRCAmut or homologous recombination deficiency (HRD) status, but an increased treatment effect was observed in the HRDpos population. QUADRA (NCT02354586) evaluated niraparib active treatment in ROC pts. Based on the results of NOVA, the primary objective in QUADRA was to determine ORR in plat sensitive, HRDpos patients. Methods: Eligible pts had grade 2 or 3 serous ROC, ≥3 prior lines of chemo and measurable disease. Pts were evaluated for BRCAmut and HRD status (MyChoice HRD Test). HRDpos included germline or tumor BRCA mutation or an HRD score ≥42. Pts received niraparib 300 mg once daily until progression; treatment emergent adverse events (TEAEs) were managed with dose reduction to 200 or 100 mg. The primary endpoint was ORR per RECIST v1.1...